Mechanism is seductive. A clean molecular story this drug hits this enzyme, therefore it prevents this complication is satisfying to teach and easy to believe. It is also where a great deal of clinical reasoning quietly goes wrong. Here is a three-word rubric that keeps mechanism claims honest, using the dicarbonyl story as the worked example. Once you have it, it travels to every therapeutic area you practice in.
Sort every mechanism claim into one of three tiers:
Demonstrated shown directly, in humans, with the relevant outcome or a validated marker.
Inferred plausible and supported indirectly, but the direct human link isn’t established.
Speculative mechanistically attractive, biologically reasonable, and essentially unproven.
Now watch what happens when you apply it to SGLT2 inhibitors, a class we (rightly) prescribe with enthusiasm.
- That SGLT2 inhibitors produce cardiovascular and renal benefit: demonstrated. EMPA-REG, CANVAS, and CREDENCE are hard-endpoint trials.
- That reduced glucose flux lowers substrate entry into the dicarbonyl pool: inferred. Reasonable, indirect, plausible.
- That the cardiorenal benefit is mediated through reduced glyoxalase-system burden: speculative. The established explanations natriuretic, hemodynamic, ketone-related, direct cardiac and renal effects are substantial, and nothing demonstrates a dicarbonyl mechanism.
The discipline here is to resist letting a proven outcome borrow credibility for your favorite mechanism. The drug works. Why it works is a separate question, held at a separate tier.
Then apply the same rubric to the graveyard of AGE-targeting drugs, which is where mechanism-worship has already cost the field years.
- Aminoguanidine trapped dicarbonyls, looked excellent in animal models, and entered clinical trials then was halted for serious toxicity, including autoimmune and vasculitic effects. Strong rationale; unacceptable drug.
- Alagebrium, an AGE cross-link “breaker,” improved arterial compliance in early trials but was discontinued. And note why the concept was fragile: it tried to cleave cross-links already formed in long-lived proteins a downstream, accumulated endpoint rather than reduce the upstream flux that generates them. Reversing established damage is a far harder pharmacological problem than preventing it.
The lesson these failures teach is not “mechanism is useless.” It’s that mechanism is a hypothesis about outcomes, not a substitute for measuring them and that where you intervene in a pathway (upstream flux vs. downstream accumulated damage) can matter more than whether your target is “correct.”
Clinical takeaway. When you next read “drug X reduces AGEs, therefore prevents complications,” pause and tier it. Is the complication benefit demonstrated, or is a demonstrated marker change being inferred forward into an outcome, or is the whole causal chain speculative? This single habit demonstrated, inferred, or speculative will sharpen how you read a drug rep’s slide, a journal abstract, and your own reasoning, in cardiology and nephrology as much as in diabetes.